HMIL's IPO had seen strong response from sovereign wealth funds and domestic mutual funds, but retail and wealthy investors sidestepped the issue amid a selloff in auto stocks and overall markets
Also plans to expand EV portfolio and production capacity
This contract follows a previous order from UPSRTC for 1,350 bus chassis, which are currently operational across Uttar Pradesh
They are updating dealership networks to offer customers a more luxurious lounge
CEAT took selective price increases during the quarter that offset part of the cost impact caused by higher rubber prices. The company remains optimistic for Q3
Kalyani emphasised that this move aligns with Bharat Forge's broader strategy to diversify its offerings in vehicle components and enter a new product segment
The domestic business achieved record-high revenue growth in double digits for the tenth consecutive quarter, driven by growth across motorcycles, commercial vehicles, and electric scooters
Dealer sources claimed that even enquiries and bookings are up by 3-4 times when compared to the last 2-3 months
BMW Group India has achieved its best-ever year-to-date car sales, with a 10 per cent growth in the first nine months of calendar year 2024
According to the company, Bajaj's use of 'Freedom' infringes on its trademark rights, which is diluting its established reputation and the goodwill cultivated over decades
Major players record 9-26% increase on strong domestic demand
A total of 300 hospitals had applied for the digital certification, which was introduced by NABH in 2023
The domestic market is expected to see a positive turnaround, with ICRA projecting revenue growth of 7-9 per cent for its sample set of companies in FY25
According to industry analysts, luxury car sales have remained steady, with a slight uptick in vehicle values driving overall revenue growth
The combined entity will have a stronger financial profile, enhanced R&D capabilities, and a streamlined supply chain, allowing it to serve global pharmaceutical clients more effectively
Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and its biosimilar, adalimumab-fkjp
Diagnostic companies like Metropolis Healthcare and Dr Lal PathLabs have implemented price hikes to cope with inflationary pressures
The sector is expected to benefit from steady cash flows and low financial leverage, which will help maintain stable credit profiles, even as pharma cos pursue acquisitions in niche therapeutic areas
Public health group objects; Indian Patent Office hearing on Thursday
Industry also faces shortages of component suppliers and talent, particularly in research and development